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Artemisinins, derived from the wormwood herb Artemisia annua, are the most potent antimalarial drugs currently
available. Despite extensive research, the exact mode of action of artemisinins has not been established. Here we use
yeast, Saccharamyces cerevisiae, to probe the core working mechanism of this class of antimalarial agents. We
demonstrate that artemisinin’s inhibitory effect is mediated by disrupting the normal function of mitochondria
through depolarizing their membrane potential. Moreover, in a genetic study, we identify the electron transport chain
as an important player in artemisinin’s action: Deletion of NDE1 or NDI1, which encode mitochondrial NADH
dehydrogenases, confers resistance to artemisinin, whereas overexpression of NDE1 or NDI1 dramatically increases
sensitivity to artemisinin. Mutations or environmental conditions that affect electron transport also alter host’s
sensitivity to artemisinin. Sensitivity is partially restored when the Plasmodium falciparum NDI1 ortholog is expressed
in yeast ndi1 strain. Finally, we showed that artemisinin’s inhibitory effect is mediated by reactive oxygen species. Our
results demonstrate that artemisinin’s effect is primarily mediated through disruption of membrane potential by its
interaction with the electron transport chain, resulting in dysfunctional mitochondria. We propose a dual role of
mitochondria played during the action of artemisinin: the electron transport chain stimulates artemisinin’s effect, most
likely by activating it, and the mitochondria are subsequently damaged by the locally generated free radicals.
Citation: Li W, Mo W, Shen D, Sun L, Wang J, et al (2005) Yeast model uncovers dual roles of mitochondria in the action of artemisinin. PLoS Genet 1(3): e36.
Introduction
Malaria, the most prevalent and pernicious parasitic disease
of humans, is estimated to kill between 1 million and 2 million
people, mainly children, each year. Resistance has emerged to
all classes of antimalarial drugs except artemisinin, an
endoperoxide antimalarial drug derived from an ancient
Chinese herbal remedy, qinghaosu. The mechanism of the
action of artemisinin remains a mystery, although iron
appears to be involved in activating this endoperoxide to
generate cytotoxic free radicals [1]. Several candidates have
been hypothesized as targets of artemisinins, including haem,
a translationally controlled tumor protein and some parasite
membrane proteins [1–3], but none of these have been
convincingly shown to be functionally relevant. Recently,
Eckstein-Ludwig et al. [4] proposed PfATP6, a sarco/endo-
plasmic reticulum Ca
2þ-ATPase, as artemisinin’s target and
inferred that artemisinin might act by mobilizing intracellular
Ca
2þstores;however, thisconclusion has also been debated [5].
One important reason for the lack of satisfying progress in
understanding artemisinin is that it is difﬁcult to carry out
genetic analysis of malaria parasites. In contrast, the yeast
Saccharamyces cerevisiae is an ideal model organism to uncover a
variety of molecular mechanisms that otherwise might be
difﬁcult to address with other systems. In this study, we
developed a yeast model and used it to probe the funda-
mental mechanisms of artemisinin’s action.
Results
Artemisinin Inhibits Yeast Growth in Nonfermentable
Media
In a pilot experiment, we tested whether artemisinin is toxic
to the growth of yeast cells. As demonstrated in Figure 1A, the
inhibitory effect of artemisinin on yeast growth in YPD (a
fermentable medium with dextrose as the carbon source)
liquid was not detectable at 8 lM, and only started to be
observable at 80 lM, a concentration far above the level
needed to inhibit the growth of Plasmodium falciparum (a 50%
growth inhibition concentration [IC50] of approximately a few
nM) [6,7]. On YPD plates, no signiﬁcant inhibition of growth is
even noticeable in the presence of 80 lM artemisinin.
This level of insensitivity to artemisinin led us to consider
whether use of the YPD media precluded our assessment of
one important organelle, the mitochondrion, in the action of
artimisinin. Yeast can grow either anaerobically or aerobi-
cally by utilizing fermentable or nonfermentable carbon
sources. In the presence of a fermentable carbon source such
as glucose (dextrose), as in YPD, yeast preferentially adopt
glycolysis to generate energy even under aerobic conditions,
and can grow normally even when mitochondrial respiration
level is minimal. In order to determine whether artemisinin
interferes with mitochondrial function, yeast was grown in
YPG or YPE media in which glucose was replaced with the
nonfermentable carbon source glycerol or ethanol. Amaz-
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when artemisinin was present. Figure 1A shows the dramatic
reduction of cell growth in the presence of 8 lM. Indeed, for
yeast grown in YPG, the IC50 (deﬁned here as 50% growth
inhibition in 48 h) was determined to be approximately 10
nM (Figure 1B), a concentration comparable to what is
effective in P. falciparum. The dramatic contrast of sensitivity
between yeast grown on artemisinin-supplemented YPD and
YPG(E) media indicates that artemisinin affects mitochon-
drial function in YPG(E).
Artemisinin Depolarizes the Mitochondrial Membrane
The observation of growth inhibition of yeast on artemi-
sinin-supplemented YPG(E) media prompted us to investigate
whether the mitochondrial membrane potential of yeast is
affected by artemisinin, because maintenance of the mem-
brane potential is key to mitochondrial functions, including
oxidative phosphorylation and metabolism of amino acids,
lipids, and haem, as well as intracellular Ca
2þ homeostasis. As
shown in Figure 1C, treatment of yeast with artemisinin
caused substantial loss of membrane potential, as evidenced
by the decreased rodamine uptake into the mitochondria.
This loss of membrane potential was also observed with yeast
grown in YPD media, but required the presence of a slightly
higher concentration of artemisinin or a longer treatment
time.
Genetic Studies Reveal Electron Transport Chain Plays
Important Roles in the Action of Artemisinin
To gain further insights into the mechanism of action of
artemisinin, we screened for yeast genes that, when inacti-
vated, can confer artemisinin resistance. A library comprised
of 4,757 homozygous deletion strains [8,9] was plated on
YPG(E) agar plates with 3–5 lM of artemisinin. Three genes
whose deletion resulted in artemisinin resistance were
identiﬁed. Two of these, NDE1 and NDI1, encode yeast
NADH dehydrogenases in the mitochondrial electron trans-
port chain [10–12]. ndi1D and nde1D displayed similar level of
growth on artemisinin-supplemented YPGE plates (Figure
2A). Overexpression of NDE1 and NDI1 in their correspond-
ing deletion strains or in the parental BY4742 background
(wild type) resulted in signiﬁcantly increased sensitivity to the
drug (Figure 2B, ﬁrst three rows). These data suggest that
NADH dehydrogenase activity is positively correlated with
yeast sensitivity to artemisinin.
In addition to NDE1 and NDI1, a third homologous yeast
gene, NDE2, is known to provide NADH dehydrogenase
activity in yeast. These NADH dehydrogenases oxidize NADH
at either the cytosolic side (Nde1p and Nde2p) or the matrix
side (Ndi1p) of the inner mitochondrial membrane. Although
deletion of NDE1 leads to a major loss of NADH dehydrogen-
ase activity at the cytosolic side, deletion of both NDE1 and
NDE2 results in complete loss of NADH dehydrogenase
activity at the cytosolic side [11–13]. Because of sequence and
function similarity between Nde1p, Ndi1p, and Nde2p, we
asked whether NDE2 interacts with artemisinin. Compared to
that of nde1D or ndi1D, nde2D manifested only marginal
Figure 1. Artemisinin Inhibits Yeast Respiratory Growth by Depolarizing the Mitochondrial Membrane
(A) Artemisinin (Art) inhibits yeast growth in nonfermentable media. In YPD the effect of artemisinin is minimal, whereas in YPG, artemisinin is highly
effective.
(B) Yeast growth is inhibited by artemisinin in YPG with an IC50 that is comparable to that required to kill cultured malaria parasites. Relative growth in
the presence of artemisinin was measured against to that of the yeast grown in the absence of artemisinin. Experiments shown were performed three
times in liquid YPG media. Error bars represent standard errors of the mean for each assay.
(C) Artemisinin depolarizes mitochondrial membrane. The peak shift toward the left represents a decrease of fluorescence signal indicating the losso f
membrane potential. Cells were grown in YPG with or without artemisinin (Art) for 2 h.
DOI: 10.1371/journal.pgen.0010036.g001
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Synopsis
Malaria kills at least 1 million people worldwide a year. Recent years
saw the rapid emergence of drug-resistant malaria strains.
Artemisinins, derived from the Chinese wormwood herb Artemisia
annua, are the most potent antimalarials currently available. Despite
extensive research, the exact mode of action of artemisinins has not
been established. In this article, Li et al. investigated yeast as a
model to probe the core working mechanism of this class of
antimalarials. They showed that artemisinin can disrupt the normal
function of mitochondria by depolarizing its membrane potential,
and that artemisinin’s effect can be affected by its interaction with
the mitochondrial electron transport chain, an apparatus that
couples oxygen oxidation and energy generation in the cell. They
proposed a dual role of mitochondria played during the action of
artemisinin: the electron transport chain likely activates artemisinin,
and the mitochondria are subsequently damaged by the locally
generated free radicals associated with this activation. The research
has provided a fine tool for the study of the mechanism of
artemisinin in a model organism (yeast), and laid the framework for
a set of possible future experiments to be conducted in yeast and
malaria parasites.resistance to artemisinin, and the double mutant nde1D nde2D
was not substantially more resistant to artemisinin than
nde1D. This is consistent with the observation that at the
cytosolic side Nde1p is the major NADH dehydrogenase and
Nde2p only plays a minor role [10–12].
Next, we investigated whether the double mutant nde1D
ndi1D is more resistant to the action of artemisinin or not.
nde1D ndi1D yeast can grow well in glucose media. However,
their growth on nonfermentable media is greatly affected (see
Figure 2A), indicating severely compromised mitochondrial
function of the strain. This growth defect precludes our
comparative analysis of nde1D ndi1D resistance against
artemisinin.
Although three NADH dehydrogenases are present in
yeast, only one such dehydrogenase, PfNDI1 (PFI0735c),
with closest homology to Ndi1p, was found in the P.
falciparum genome database [13]. Similarly, Nde1p and
Nde2p do not have counterparts in mammalian cells, which
utilize redox shuttle mechanisms to couple cytosolic NADH
oxidation to NADH dedydrogenase (complex I) in the
matrix side. To test whether PfNDI1 expression in yeast
confers artemisinin’s sensitivity, PfNDI1 was ampliﬁed from
a cDNA pool of P. falciparum. As expected, expression of
PfNDI1 in ndi1D background partially restored its sensitivity
to artemisinin (Figure 2C). This indicates that PfNDI1
expressed in yeast interacts with artemisinin in a similar
fashion to Ndi1p.
The third artemisinin-resistant strain is sip5D (Figure 2A).
Little is known about Sip5p except that it biochemically
interacts with Snf1 protein kinase and Reg1/Glc7 protein
phosphatase [14], both of which are involved in the
regulation of alternative carbon source utilization and
respiration. Thus, it is possible that SIP5 somehow indirectly
affects energy generation, or, more speciﬁcally, mitochon-
drial respiration. To test the hypothesis that respiration
control is involved in artemisinin resistance, mutants of
seven other components involved in carbon-source regula-
tion and respiration [15] were examined. Most of them are
variably resistant to the action of artemisinin (see Materials
and Methods).
The epistatic relationship of SIP5 with NDI1 or NDE1 was
also explored. Overexpression of SIP5 in the control strain,
ndi1D or nde1D did not have any effect on sensitivity or
resistance to artemisinin. In contrast, when either NDI1 or
NDE1 is overexpressed in sip5D background, yeast still exhibit
hypersensitivity to artemisinin. These ﬁndings suggest that
sip5D affects artemisinin resistance indirectly by acting on the
electron transport chain. The identiﬁcation of these three
genes that are directly or indirectly involved in respiration
reinforced our previous interpretation that artemisinin acts
through mitochondria.
Because the electron transport chain is involved in the
action of artemisinin, we asked further whether other
components downstream of NADH dehydrogenase interact
with artemisinin. We have checked available deletion
mutants (25 strains altogether) of other known genes in the
electron transport chain for possible artemisinin resistance.
Although some of these strains cannot grow on nonferment-
able media, of those that can, none appears to be resistant to
the action of artemisinin (see Materials and Methods).
Although it is likely some of these mutants have impaired
electron transport activity, the fact that all 25 deletion
strains do not manifest either artemisinin hypersensitivity or
artemisinin resistance (compared to the wild-type strain)
implies that not all components of the pathway interact with
artemisinin.
Artemisinin’s Action Generates Reactive Oxygen Species
Generation of oxidative stress is believed to be involved in
the antiparasitic effects of artemisinin [16]. Figure 3A shows
that the levels of reactive oxygen species (ROS) produced in
three strains after treatment with artemisinin positively
correlated with their levels of sensitivity to artemisinin. We
thus investigated whether the artemisinin-resistant mutants
that we isolated were cross-resistant to other oxidative agents.
Unexpectedly, these mutants did not show resistance to
peroxide or paraquat, and, if anything, manifested hyper-
Figure 2. The Genetic Screen for Artemisinin-Resistant Mutations
Identified Genes in the Electron Transport Chain or in the Pathway of
Respiratory Control
(A) The three mutants isolated display increased resistance to
artemisinin. YPGE plates with or without 4 lM artemisinin were used.
nde1D ndi1D exhibited severe growth defect in nonfermentable media.
(B) Increased activities of NADH dehydrogenases exacerbate artemisinin
sensitivity, and Sip5 may be positioned upstream of NADH dehydro-
genases. Plates are all SG-Ura (with or without 4 lM artemisinin) to
prevent plasmid loss. ADH1-NDE1 and ADH1-SIP5 here denote constructs
that express NDE1 and SIP5 under the control of ADH1 promoter. The
results of ADH1-NDI1 are similar to that of ADH1-NDE1 and are not shown
on the two plates.
(C) Expression of PfNDI1 in ndi1D restores yeast sensitivity to artemisinin.
Plates used here are SG-Ura (with or without 8 lM artemisinin).
Art, artemisinin; SG, synthetic yeast media with glycerol as the carbon
source; WT, wild type.
DOI: 10.1371/journal.pgen.0010036.g002
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Mode of Action of Artemisininsensitivity to these oxidative agents (Figure 3B). On the other
hand, although sod1D and sod2D mutants display increased
sensitivity to oxidative stress, neither of them exhibited more
sensitivity to artemisinin than the wild type (result not
shown). This result, combined with the observation that yeast
cells are unaffected by artemisinin in YPD, suggests that
artemisinin is not simply a promiscuous oxidant. Instead, we
suggest that artemisinin may have local effects on the
mitochondria.
Because activation of artemisinin is known to depend upon
the cleavage of a peroxide bridge via an iron-dependent
mechanism [17], we investigated the interaction between iron
and artemisinin in yeast. When bathophenanthrolinedisul-
fonic acid (BPS), an iron chelator, was added into YPG media
together with 8 lM artemisinin, the inhibitory effect of
artemisinin on growth was attenuated (Figure 3C). In a
separate series of experiments to determine whether extra
iron could aggravate the effect of artemisinin, we added
between 1 and 100 lMF e
2þ or Fe
3þ to the plates. At these
concentrations iron-enhanced toxicity was not observed. In
addition, incubation with iron before artemisinin exposure
does not exacerbate yeast sensitivity to artemisinin. These
results suggest iron plays an important role in the activation
of artemisinin, but additional iron above a certain threshold
level has no further effect. This is in agreement with the
report that artemisinin can also effectively kill parasites at
stages that lack haemozoin [18].
Discussion
In this report we developed a sensitive yeast model to
analyze the action of artemisinin. We demonstrated that
artemisinin is able to depolarize the mitochondrial mem-
brane and that increased electron transport activity increases
the sensitivity of the cell to artemisinin. Further, we showed
artemisinin produces an increase in ROS by a mechanism
that differs from that of general oxidants.
Although low amounts of artemisinin affect yeast growth
only in nonfermentable media, in both YPG(E) and YPD
media artemisinin depolarizes the mitochondrial membrane.
The fact that YPD slightly attenuates the effect of artemisinin
in depolarizing mitochondrial membrane potential is possi-
bly due to the partial repression of the activity of respiration
enzymes (including NDI1 and NDE1) by glucose [19]. Likewise,
mutations that indirectly affect respiration will possibly also
affect artemisinin sensitivity. The positive correlation ob-
served between respiration activity and sensitivity to artemi-
sinin suggests that the electron transport chain acts to
stimulate the activity of artemisinin. As such, the mitochon-
drial electron transport chain per se does not seem to be the
primary target of artemisinin; instead, the electron transport
chain seems to play a role in activating artemisinin. The
activated artemisinin may then locally depolarize the mito-
chondrial membrane, impeding many functions dependent
upon its potential. Although the disruption of mitochondrial
Figure 3. Artemisinin Generates ROS in Yeast
When applicable, 8 lM artemisinin was used.
(A) Artemisinin-resistant strains generate fewer ROS. Yeast untreated with artemisinin was used as the control. The experiment was performed three
times with similar results. NDE1 denotes the overexpressor strain of NDE1 driven by ADH1 promoter.
(B) Isolated artemisinin-resistant strains are not cross-resistant to paraquat or peroxide. Shown here are the wild-type (WT) parental strain (BY4742),
nde1D and ndi1D on YPD plates without or with 0.02% paraquat.
(C) Iron is possibly involved in artemisinin (Art) activation. Addition of BPS to the medium reduces yeast’s sensitivity to artemisinin, whereas BPS alone
does not enhance general yeast survival on drug-free plates. We did not use a higher amount of BPS to further reduce the iron level because a severe
reduction in iron dramatically affects yeast growth on YPG.
DOI: 10.1371/journal.pgen.0010036.g003
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Mode of Action of Artemisininfunction does not dramatically affect yeast growth in YPD
media, for P. falciparum, loss of membrane potential will
additionally affect pyrimidine biosynthesis [20], a key
metabolic process for the survival of the parasite. This
proposed mode of action for artemisinin differs from that of
atovaquone, a broad-spectrum antiparasitic drug, which has
been shown to inhibit complex III of the electron transport
chain and, consequently, collapse mitochondrial membrane
potential and kill P. falciparum [21].
Our ﬁndings indicate that iron is involved in the action of
artemisinin. Mitochondria are well known to be a rich source
of transition metals, including iron and copper. Conceivably,
an active electron transport chain provides the electron
source to Fe-S in catalyzing artemisinin and produces
carbon-centered free radicals. Although we cannot exclude
the possibility that other components in the electron trans-
porting chains may interact with artemisinin, our current
ﬁndings suggest that limited components, including NADH
dehydrogenases, are involved in this process.
Distinctive ultrastructural changes have been noted in
artemisinin-treated P. falciparum, including marked swelling
of the mitochondria, followed by the appearance of electron-
dense chromatin materials in the nuclei, clumping of
ribosomes, nuclear membrane blebbing, and segregation of
the nucleoplasm [22–26]. At high artemisinin concentration,
even mammalian cells partially lose their mitochondria
function [27,28]. These observations are consistent with a
primary role of mitochondria in the action of artemisinin,
whereas other physiological changes are probably secondary.
Not surprisingly, P. falciparum has a functional mitochondrial
electron transport system and an oxygen-requiring system
that is necessary for growth and survival [29–31]. The relative
insensitivity of mammalian cells to artemisinins may be due
to the fundamental structural difference of their electron
transport chains; for example, human complex I is composed
of at least 43 components whereas its counterparts in yeast
and P. falciparum are much simpler (one polypeptide chain).
Indeed, a BLAST search with Nde1p or Ndi1p as a query
revealed no signiﬁcant homolog in the human genome. Even
more, no signiﬁcant homologs could be found in available
National Center for Biotechnology Information (NCBI)
databases across the whole Metazoan kingdom, indicating
NADH dehydrogenase is not evolutionarily highly conserved
between yeast and Metazoa.
The yeast model provides us with insights into mode of
action of artemisinin: It interacts with the electron transport
chain, generates local ROS, and causes the depolarization of
the mitochondrial membrane. This scheme agrees with what
we know about the chemical properties of artemisinin and
ﬁndings in malaria studies. Although some physiological
differences exist between yeast and malarial parasites, the
pathway or basic principles that we have derived in our
studies of artemisinin in yeast should aid future malaria
research. The yeast model that we have developed provides a
new way to probe the action of artemisinin. Our ﬁndings
suggest many future genetic and biochemical analyses of this
natural, powerful, and mysterious drug.
Materials and Methods
Yeast growth and library screen. Standard yeast media and growth
conditions were used. The yeast deletion library used is a collection of
4,757 homozygous diploid S. cerevisae strains (BY4743: MATa/MATa ´
his3D1/his3D1 leu2D0/leu2D0 lys2D0/þ met15D0/þ ura3D0/ura3D0) in
which each strain has a single open reading frame replaced with the
KanMX4 module. We used homozygous diploid strain library for the
original screen because haploid strain appears to have a relatively
higher rate of screening background, presumably due to spontaneous
mutation. An aliquot of the pooled yeast library was plated on YPG
(2% glycerol as carbon source) or YPE (3% ethanol as carbon source)
agar plates supplemented with 3–5 lM artemisinin. (Altogether about
100,000 total colonies were plated). Artemisinin-resistant colonies
were isolated, and serial dilutions were made and spotted on
artemisinin plates to conﬁrm the original phenotype. About a dozen
relatively more resistant colonies were chosen, and the correspond-
ing genes were identiﬁed by bubble PCR or inverse PCR and DNA
sequencing analysis. Phenotypes of these mutants were further
conﬁrmed in haploid background (BY4742: MATa his3D1 leu2D0
lys2D0 ura3D0).
Artemisinin sensitivity/resistance assay. For growth in liquid, yeast
were grown overnight in YPD medium, spun down, washed three
times with YPG medium, and diluted to an A600 of 0.5. Then, 10 ll was
inoculated into YPD or YPG media with or without artemisinin, and
A600 was measured over time. For growth on agar plates, yeast
previously grown in liquid YPD was spotted with 10-fold serial
dilutions.
Besides SIP5, genes that may be involved in carbon-source
utilization were individually checked for artemisinin sensitivity/
resistance. These include GAL83, SIP1,  2,  3, and  4, and SNF1 and
 4. snf1 cannot grow on YPG. sip1D, sip3D, sip4D, and gal83D display
artemisinin resistance.
Mutants of genes in the electron transport chain, including SDH1,
 2, 3, and 4, COR1, CYT1, QCR2, 6, 7, 8, 9, and -10, RIP1, INH1,
STF1 and -2, and COX4,  5A,  5B,  6,  7,  8,  9,  12, and -13 were
individually examined for artemisinin resistance. Among these, SDH1
and -3, CYT1, QCR9, and COX4, 6, 7, and -13 are required for yeast
growth on YPG media, precluding analysis of their involvement in
artemisinin’s action.
Gene deletion and expression. Gene replacement was achieved by
homologous recombination with URA3 or LEU2 as the replacement
marker in strain BY4742 background. Gene deletions were veriﬁed
by PCR. For expression, SIP5, NDI1, NDE1, and PfNDI1 were PCR
ampliﬁed from BY4743 genomic DNA or a cDNA library of P.
falciparum. Ampliﬁed target DNAs were then cloned into an ADH1-
driven expression vector (pADH1-YES2, a vector modiﬁed from
pYES2 from Invitrogen (Carlsbad, California, United States), in
which the GAL1 promoter was replaced with an ADH1 promoter).
Yeast transformation was done by the lithium acetate method.
Transformed cells were selected on SD-Ura. Sequences for PCR
primers used for SIP5, NDI1, NDE1, and PfNDI1 are available by
request.
Analysis of ROS production. Flow cytometric analysis was used to
assay the production of free intracellular radicals. Brieﬂy, cells were
incubated with dihydrorhodamine 123 for 2 h and then analyzed by a
FACS Calibur (Becton Dickinson, San Jose, California, United States)
at a low ﬂow rate with excitation and emission settings of 488 and
525–550 nm (ﬁlter FL1), respectively.
Assay of the electrochemical potential. After treatment in 20 mM
HEPES buffer (pH 7.4) containing 50 mM glucose, 1 ml of the cell
suspension was incubated with 2 lM Rh123 (rhodamine 123) for 30
min, washed, and then resuspended in 100 ll PBS. Mitochondrial
electrochemical potential was expressed as the ﬂuorescence intensity
of Rh123, which was read through a FACS Calibur (Becton Dickinson)
with excitation at 480 nm and emission at 530 nm.
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